Lampichler, Katharina
Semmler, Georg
Wöran, Katharina
Simbrunner, Benedikt
Jachs, Mathias
Hartl, Lukas
Bauer, David Josef Maria
Balcar, Lorenz
Burghart, Lukas
Trauner, Michael
Tamandl, Dietmar
Ba-Ssalamah, Ahmed
Mandorfer, Mattias
Reiberger, Thomas http://orcid.org/0000-0002-4590-3583
Scheiner, Bernhard
Scharitzer, Martina
Funding for this research was provided by:
Medizinisch-Wissenschaftlichen Fonds des Bürgermeisters der Bundeshauptstadt Wien (18062)
Ärztekammer für Wien (0023-WS2020)
Article History
Received: 1 July 2022
Revised: 6 August 2022
Accepted: 29 August 2022
First Online: 27 September 2022
Declarations
:
: The scientific guarantor of this publication is Thomas Reiberger.
: The authors have nothing to disclose regarding the work under consideration for publication. The following authors disclose conflicts of interests outside the submitted work: KL, KW, MJ, LH, and LB have nothing to disclose. GS received travel support from Gilead. BSi received travel support from Abbvie and Gilead. DB received travel support from AbbVie and Gilead. MP is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, Lilly, and MSD; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. MT received grant support from Albireo, Almylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and Ultragenyx, and honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex, Pliant and Regulus, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept and MSD, as well as travel support from AbbVie, Falk, Gilead, and Intercept. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid. MM served as a speaker and/or consultant and/or advisory board member for AbbVie, Collective Acumen, Gilead, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. DT is an investigator for Roche. He received travel support from Siemens and Bayer. JS received grant support from Eli Lilly and Company and Gilead. AB-S received honoraria for lectures and consultancy fees from Bayer. TR received grant support from AbbVie, Boehringer-Ingelheim, Gilead, MSD, Gore, Philips Healthcare, Pliant Pharmaceuticals, Siemens; speaking honoraria from AbbVie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. BS received travel support from AbbVie, Ipsen, and Gilead. MS received travel support from Bayer, speaker honoraria from Takeda, and is an investigator for Böhringer, Takeda, Allena Pharmaceuticals, and Gilead.
: Several authors have significant statistical expertise. Also, no complex statistical methods were necessary for this paper.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: In a prior study, we reported on the clinical characterization of patients with PSVD, being the first of its kind, as well as differences to patients meeting the former definition of INCPH [CitationRef removed]. This study included 91 patients with PSVD. Also, data on cirrhotic patients included in the prospective VICIS study (ExternalRef removed identifier: NCT03541057) have been previously published (e.g., on 234 in the referred study) as this is a prospective registry study with consecutive sampling [CitationRef removed].References1. Wöran K, Semmler G, Jachs M et al (2020) Clinical course of porto-sinusoidal vascular disease is distinct from idiopathic noncirrhotic portal hypertension. Clin Gastroenterol Hepatol. 10.1016/j.cgh.2020.11.0392. Simbrunner B, Semmler G, Stadlmann A et al (2020) Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatol Int 14:1093-1103
: • retrospective• Case control study• performed at one institution